Cours suspendu

Communiqués Applied Therapeutics, Inc.

Actions

APLT

US03828A1016

Recherche biotechnologique et médicale

Temps Différé Nasdaq Autres places de cotation 22:00:00 02/02/2026			Varia. 5j.	Varia. 1 janv.
0,1030 ^USD	+0,19%		-.--%	+3,00%

03/02	Cycle Group Holdings Limited finalise l'acquisition d'Applied Therapeutics, Inc. (NasdaqCM:APLT) pour environ 14,3 millions de dollars	CI
03/02	Applied Therapeutics, Inc. annonce des changements au sein de sa direction	CI

Communiqués

30/01	Cycle Pharmaceuticals Announces Further Extension of Applied Therapeutics Tender Offer	AQ
29/01	Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension	GL
11/12	Cycle Pharmaceuticals to Acquire Applied Therapeutics	GL
20/11	Applied Therapeutics Announces Corporate Updates	GL
14/11	Applied Therapeutics Reports Third Quarter 2025 Financial Results	AQ
13/11	Applied Therapeutics Reports Third Quarter 2025 Financial Results	GL
29/09/25	Applied Therapeutics Provides Update Following Meeting with FDA	GL
13/08/25	Applied Therapeutics Reports Second Quarter 2025 Financial Results	GL
17/06/25	Applied Therapeutics Announces Key Leadership Appointments	GL
18/05/25	Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting	AQ
18/05/25	Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting	GL
14/05/25	Amended Complaint Filed In Securities Class Action Against Applied Therapeutics	AQ
13/05/25	Applied Therapeutics Reports First Quarter 2025 Financial Results	GL
09/05/25	Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting	GL
14/04/25	Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results	GL
31/03/25	Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission	GL
19/03/25	Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer	GL
18/02/25	Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky	PR
14/02/25	Applied Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT	PR
13/02/25	Shareholders of Applied Therapeutics, Inc. Should Contact The Gross Law Firm Before February 18, 2025 to Discuss Your Rights - APLT	PR
11/02/25	Class Action Filed Against Applied Therapeutics, Inc. (APLT) - February 18, 2025 Deadline to Join - Contact Levi & Korsinsky	PR
10/02/25	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit - APLT	PR
06/02/25	The Gross Law Firm Reminds Applied Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT	PR
04/02/25	Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT	PR
03/02/25	Applied Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - APLT	PR